Novel bispecific antibodies in CD20-positive B-cell non-Hodgkin lymphomas
Novel bispecific antibodies in CD20-positive B-c
Zanubrutinib in relapsed/refractory marginal zone lymphoma: MAGNOLIA
Zanubrutinib in relapsed/refractory marginal zon
Mantle cell lymphoma: improving outcomes in difficult-to-treat patient populations
Mantle cell lymphoma: improving outcomes in diff
Extending anti-PD-1–based options in the setting of Hodgkin lymphoma
Extending anti-PD-1–based options in the setting
Successful inhibition of PI3K, BTK, BCL2 and other targets in various B-cell malignancies
Successful inhibition of PI3K, BTK, BCL2 and oth
Waldenström’s macroglobulinemia: outcome optimization via combinations
Waldenström’s macroglobulinemia: outcome optimiz
CLL/SLL: current perspectives across a range of potent agents
CLL/SLL: current perspectives across a range of
Preface – ASCO/EHA/ICML 2021
Preface – ASCO/EHA/ICML 2021 Véronique
